Novartis AG Remains Hush-Hush About CAR-T Trial But the FDA is Impressed and Thinks It's a Breakthrough
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x400-novartis.jpg" NAME"Novartis AG Remains Hush-Hush About CAR-T Trial But the FDA is Impressed and Thinks It's a Breakthrough" ALT"Novartis AG Remains Hush-Hush About CAR-T Trial But the FDA is…
Cancer Biotech G1 Therapeutics Files for $115 Million IPO
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks.jpg" NAME"Cancer Biotech G1 Therapeutics Files for $115 Million IPO" ALT"Cancer Biotech G1 Therapeutics Files for $115 Million IPO"April 18, 2017By Alex Keown, BioSpace.com Breaking News StaffRALEIGH, N... Source:…
How Pfizer Made Most of Its $52.8 Billion Last Year
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x425-pfizer.jpg" NAME"How Pfizer Made Most of Its $52.8 Billion Last Year" ALT"How Pfizer Made Most of Its $52.8 Billion Last Year"April 18, 2017By Mark Terry, BioSpace.com Breaking News StaffIn…
Theranos, Reach Agreement On Full Restitution To State Consumers
Life Sciences Jobs ... Source: BioSpace
When It Rains, It Pours: Bay Area's OncoMed Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks2.jpg" NAME"When It Rains, It Pours: Bay Area's OncoMed Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study" ALT"When It Rains, It Pours: Bay Area's…
How Biogen Lost Its Chance to Be the Hunter and Became the Hunted in Just a Few Months
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x470-biogen.jpg" NAME"How Biogen Lost Its Chance to Be the Hunter and Became the Hunted in Just a Few Month" ALT"How Biogen Lost Its Chance to Be the Hunter and…
- Go to the previous page
- 1
- …
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- …
- 288
- Go to the next page